Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lifeward Q3 2026 Results: Net Loss of $5.05M, Loss Widens

Lifeward Ltd. reported its financial results for the quarter ended September 30, 2026, highlighting the recent acquisition of Oratech Pharmaceuticals Ltd. and the ongoing transition to a channel-partner distribution model. The company expressed substantial doubt regarding its ability to continue as a going concern, noting the urgent need for additional financing to fund operations and clinical trials for ORMD-0801.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue5.46.2
Gross profit1.52.7
Profit before tax-5.0-3.2
Net income-5.1-3.2
EPS (diluted, $ a share)$-1.32$-2.37

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-12.4%
Gross margin27.4%
Operating margin-110.0%
Source

10-Q filed with the SEC, NASDAQ: LFWD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lifeward Ltd.: key numbers

Share price
$3.10Close, Nov 17
Market cap
$8.8M
Shares outstanding
2.84MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lifeward Ltd.

All →
9:26 AM ET 8-K
Financial Results

Lifeward Financial Results

Lifeward Ltd. reported Q3 2026 financial results, highlighted by an 18% year-over-year increase in AlterG revenue to $3.6 million. The company is transitioning its ReWalk exoskeleton business to a capital-efficient channel-partner distribution model, including a pilot program with Ottobock Care, to expand patient access and reduce operating expenses.

Term
Q3 2026

“Our third quarter results reflect the continued momentum of AlterG, which delivered its second consecutive quarter of double-digit year-over-year revenue growth. We are also making significant progress in our strategic transition of ReWalk to a channel-partner model, which we believe is the most effective way to scale this business and bring our life-changing technology to more patients.”

Larry Jasinski, Chief Executive Officer

“We remain focused on driving commercial execution and managing our resources effectively as we advance our transition to a channel-partner model for ReWalk. We believe this model will allow us to reach more patients while improving our operating efficiency and cash flow over the long term.”

Ronen Tsimerman, Chief Financial Officer
4:33 PM ET 8-K
Shareholder Meeting

Lifeward Shareholder Meeting

Lifeward Ltd. held its 2026 Annual and Extraordinary General Meeting of Shareholders on October 30, 2026. Shareholders approved the re-election of Haggai Zamir and Avi Gabay as Class III directors, the election of Ariel Kallner as an external director, and compensation packages for directors and Interim CEO Josh Hexter; however, Proposal 6 did not receive the requisite votes for approval.

8:56 AM ET 8-K
Executive Compensation

Lifeward Executive Compensation

Lifeward Ltd. appointed Ronen Tsimerman as Chief Financial Officer, effective November 1, 2026. The appointment includes an employment agreement with a gross monthly base salary of NIS 70,000 and a target annual performance-based bonus of at least four monthly salaries, subject to shareholder approval of a renewed compensation policy.

Counterparty
Ronen Tsimerman
4:31 PM ET 8-K
Leadership Change

Lifeward Leadership Change

Rami Aviram, who was previously appointed as Chief Financial Officer effective November 1, 2026, has informed Lifeward Ltd. that he will no longer join the company. Josh Hexter will continue to serve as the interim principal financial and accounting officer while the company resumes its search for a permanent CFO.

Counterparty
Rami Aviram
8:30 AM ET 8-K
Leadership Change

Lifeward Leadership Change

Lifeward Ltd. announced that Almog Adar's departure as CFO became effective on September 30, 2026. Interim CEO Josh Hexter has been designated to serve as the interim principal financial and accounting officer until Rami Aviram assumes the CFO role on November 1, 2026.

5:14 PM ET 8-K
Shareholder Meeting

Lifeward Shareholder Meeting

Lifeward Ltd. has scheduled its 2026 Annual and Extraordinary General Meeting of Shareholders for October 30, 2026. Because the meeting date is more than 30 days from the anniversary of the prior year's meeting, the company established September 23, 2026, as the deadline for shareholder proposals and director nominations.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.